Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 488

1.

Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.

Rossi J, Bayram M, Udelson JE, Lloyd-Jones D, Adams KF, Oconnor CM, Stough WG, Ouyang J, Shin DD, Orlandi C, Gheorghiade M.

Acute Card Care. 2007;9(2):82-6.

PMID:
17573581
[PubMed - indexed for MEDLINE]
2.

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.

JAMA. 2007 Mar 28;297(12):1319-31. Epub 2007 Mar 25.

PMID:
17384437
[PubMed - indexed for MEDLINE]
3.

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.

Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C; Tolvaptan Investigators.

Circulation. 2003 Jun 3;107(21):2690-6. Epub 2003 May 12.

PMID:
12742979
[PubMed - indexed for MEDLINE]
Free Article
4.

Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study.

Filippatos G, Rossi J, Lloyd-Jones DM, Stough WG, Ouyang J, Shin DD, O'connor C, Adams KF, Orlandi C, Gheorghiade M.

J Card Fail. 2007 Jun;13(5):360-4.

PMID:
17602982
[PubMed - indexed for MEDLINE]
5.

Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study.

Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF Jr, Califf RM, Gheorghiade M; OPTIME-CHF Investigators.

Circulation. 2005 May 17;111(19):2454-60. Epub 2005 May 2.

PMID:
15867182
[PubMed - indexed for MEDLINE]
Free Article
6.

Impact of change in serum sodium concentration on mortality in patients hospitalized with heart failure and hyponatremia.

Madan VD, Novak E, Rich MW.

Circ Heart Fail. 2011 Sep;4(5):637-43. doi: 10.1161/CIRCHEARTFAILURE.111.961011. Epub 2011 Jun 14.

PMID:
21673193
[PubMed - indexed for MEDLINE]
Free Article
7.

Hyponatremia in acute heart failure syndromes: a potential therapeutic target.

Brandimarte F, Fedele F, De Luca L, Fonarow GC, Gheorghiade M.

Curr Heart Fail Rep. 2007 Dec;4(4):207-13. Review.

PMID:
18221617
[PubMed - indexed for MEDLINE]
8.

Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry.

Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, She L, Yancy CW, Young J, Fonarow GC; OPTIMIZE-HF Investigators and Coordinators.

Eur Heart J. 2007 Apr;28(8):980-8. Epub 2007 Feb 19.

PMID:
17309900
[PubMed - indexed for MEDLINE]
Free Article
9.

Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction.

Rusinaru D, Buiciuc O, Leborgne L, Slama M, Massy Z, Tribouilloy C.

Am J Cardiol. 2009 Feb 1;103(3):405-10. doi: 10.1016/j.amjcard.2008.09.091. Epub 2008 Nov 19.

PMID:
19166698
[PubMed - indexed for MEDLINE]
10.

Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial.

Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Piña IL, Fonarow GC, DeMarco T, Pauly DF, Rogers J, DiSalvo TG, Butler J, Hare JM, Francis GS, Stough WG, O'Connor CM.

Arch Intern Med. 2007 Oct 8;167(18):1998-2005.

PMID:
17923601
[PubMed - indexed for MEDLINE]
11.

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators.

N Engl J Med. 2006 Nov 16;355(20):2099-112. Epub 2006 Nov 14.

PMID:
17105757
[PubMed - indexed for MEDLINE]
Free Article
12.

EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.

Cavalcante JL, Khan S, Gheorghiade M.

Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1331-8. doi: 10.1586/14779072.6.10.1331.

PMID:
19018685
[PubMed - indexed for MEDLINE]
13.

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.

Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators.

JAMA. 2004 Apr 28;291(16):1963-71.

PMID:
15113814
[PubMed - indexed for MEDLINE]
14.

Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.

Nemerovski C, Hutchinson DJ.

Clin Ther. 2010 Jun;32(6):1015-32. doi: 10.1016/j.clinthera.2010.06.015. Review.

PMID:
20637957
[PubMed - indexed for MEDLINE]
15.

Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.

Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC Jr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade M; EVEREST Investigators.

J Am Coll Cardiol. 2008 Nov 11;52(20):1640-8. doi: 10.1016/j.jacc.2008.07.056.

PMID:
18992654
[PubMed - indexed for MEDLINE]
Free Article
16.

Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF).

Klein L, Massie BM, Leimberger JD, O'Connor CM, Piña IL, Adams KF Jr, Califf RM, Gheorghiade M; OPTIME-CHF Investigators.

Circ Heart Fail. 2008 May;1(1):25-33. doi: 10.1161/CIRCHEARTFAILURE.107.746933.

PMID:
19808267
[PubMed - indexed for MEDLINE]
Free Article
17.

Comparison of 60-day mortality in hospitalized heart failure patients with versus without hypothermia.

Payvar S, Orlandi C, Stough WG, Elkayam U, Ouyang J, Casscells SW, Gheorghiade M; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators.

Am J Cardiol. 2006 Dec 1;98(11):1485-8. Epub 2006 Oct 16.

PMID:
17126655
[PubMed - indexed for MEDLINE]
18.

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.

JAMA. 2007 Mar 28;297(12):1332-43. Epub 2007 Mar 25.

PMID:
17384438
[PubMed - indexed for MEDLINE]
19.

Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.

Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.

Cardiovasc Drug Rev. 2007 Spring;25(1):1-13. Review.

PMID:
17445084
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk